NCI Cancer Bulletin: A Trusted Source for Cancer Research NewsNCI Cancer Bulletin: A Trusted Source for Cancer Research News
June 1, 2004 • Volume 1 / Number 22 E-Mail This Document  |  Download PDF  |  Bulletin Archive/Search  |  Subscribe

NCI Cancer Bulletin Archive

Page Options

  • Print This Page
  • Print This Document
  • View Entire Document
  • Email This Document
  • View/Print PDF

The information and links on this page are no longer being updated and are provided for reference purposes only.

Funding Opportunities

NCI's Division of Cancer Prevention will present a week-long course in molecular prevention
August 2-6.

for more information and to register.

Cellular and Genetic DiscoveryToward Curative Therapy in Myeloproliferative Disorders (MPD)

RFA HL-04-034
Letter of Intent Receipt Date: Jan. 16, 2005
Application Receipt Date: Feb. 16, 2005

This RFA solicits applications for research to identify new cellular and genetic markers associated with the origin and progression of myeloproliferative disorders (MPD) that can be applied to the future development of novel therapeutics with curative intent. MPDs represent a broad range of clinical entities, which creates difficulties in prompt assignment of diagnosis, prediction of prognosis, characterization of disease evolution, and research on the etiology and progression of disease.

This RFA will use the R01 award mechanism.

For more information see

Inquiries: Dr. R. Allan Mufson,

Reducing Barriers to Symptom Management and Palliative Care

Letter of Intent Receipt Date: Aug. 24, 2004
Application Receipt Date: Sept. 24, 2004

This RFA is to solicit applications for research directed at developing and testing interventions to reduce or overcome barriers to the delivery of appropriate symptom management and palliative care for persons living with cancer, thereby decreasing suffering and improving health and quality of life. Relative research should: 1) generate knowledge about how to reduce barriers to delivery of symptom management and palliative care, 2) address barriers for vulnerable, medically underserved, and special populations to access and receive palliative care, and 3) encourage research collaborations across disciplines.

This RFA will use NIH R01 (research project grant) and R21 (exploratory/developmental grant) award mechanisms.

For more information see

Inquiries: Dr. Ann O'Mara,